Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NYSE:OGN NYSE:QGEN NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.27-0.5%$49.40$21.72▼$54.60$9.81B1.252.93 million shs201,295 shsOGNOrganon & Co.$10.36-1.8%$9.73$8.01▼$19.73$2.69B0.64.40 million shs357,072 shsQGENQIAGEN$45.13-1.0%$48.14$37.63▼$51.88$10.04B0.641.37 million shs181,826 shsROIVRoivant Sciences$14.63-0.8%$12.35$8.73▼$16.05$9.99B1.156.10 million shs1.37 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-0.08%+0.02%+4.93%+16.04%+102.76%OGNOrganon & Co.-0.12%+2.08%+12.15%+5.65%-46.42%QGENQIAGEN-0.25%+0.01%-8.27%-3.95%+5.50%ROIVRoivant Sciences-1.34%+3.95%+23.66%+29.30%+23.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.27-0.5%$49.40$21.72▼$54.60$9.81B1.252.93 million shs201,295 shsOGNOrganon & Co.$10.36-1.8%$9.73$8.01▼$19.73$2.69B0.64.40 million shs357,072 shsQGENQIAGEN$45.13-1.0%$48.14$37.63▼$51.88$10.04B0.641.37 million shs181,826 shsROIVRoivant Sciences$14.63-0.8%$12.35$8.73▼$16.05$9.99B1.156.10 million shs1.37 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-0.08%+0.02%+4.93%+16.04%+102.76%OGNOrganon & Co.-0.12%+2.08%+12.15%+5.65%-46.42%QGENQIAGEN-0.25%+0.01%-8.27%-3.95%+5.50%ROIVRoivant Sciences-1.34%+3.95%+23.66%+29.30%+23.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$63.9424.73% UpsideOGNOrganon & Co. 2.80Moderate Buy$17.3367.39% UpsideQGENQIAGEN 2.27Hold$49.6910.09% UpsideROIVRoivant Sciences 3.00Buy$19.9436.32% UpsideCurrent Analyst Ratings BreakdownLatest OGN, QGEN, BBIO, and ROIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025ROIVRoivant SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.009/18/2025ROIVRoivant SciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $24.009/18/2025ROIVRoivant SciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $21.009/18/2025ROIVRoivant SciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$16.00 ➝ $20.009/18/2025ROIVRoivant SciencesBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$12.00 ➝ $16.509/18/2025ROIVRoivant SciencesLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $22.009/18/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.009/15/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.009/12/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $82.009/3/2025BBIOBridgeBio PharmaJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$55.00 ➝ $70.009/2/2025ROIVRoivant SciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight ➝ Buy$16.00(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M44.17N/AN/A($7.71) per share-6.65OGNOrganon & Co.$6.40B0.42$4.82 per share2.15$1.83 per share5.66QGENQIAGEN$1.98B5.07$3.16 per share14.27$16.05 per share2.81ROIVRoivant Sciences$23.23M429.87N/AN/A$7.45 per share1.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)OGNOrganon & Co.$864M$2.693.852.770.9611.15%163.88%6.99%10/30/2025 (Estimated)QGENQIAGEN$83.59M$1.6926.6818.352.4118.30%14.77%8.87%11/5/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)Latest OGN, QGEN, BBIO, and ROIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million8/5/2025Q2 2025OGNOrganon & Co.$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billion8/5/2025Q2 2025QGENQIAGEN$0.60$0.60N/A$0.44$523.97 million$533.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.77%N/A2.97%N/AQGENQIAGEN$0.250.55%N/A14.79%N/AROIVRoivant SciencesN/AN/AN/AN/AN/ALatest OGN, QGEN, BBIO, and ROIV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/5/2025OGNOrganon & Co.quarterly$0.020.9%8/15/20258/15/20259/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A5.195.08OGNOrganon & Co.11.981.651.13QGENQIAGEN0.251.611.35ROIVRoivant SciencesN/A40.5440.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%OGNOrganon & Co.77.43%QGENQIAGEN70.00%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%OGNOrganon & Co.1.40%QGENQIAGEN9.00%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableOGNOrganon & Co.4,000259.97 million256.33 millionNot OptionableQGENQIAGEN5,765222.29 million202.29 millionOptionableROIVRoivant Sciences860682.88 million609.13 millionOptionableOGN, QGEN, BBIO, and ROIV HeadlinesRecent News About These CompaniesInsider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 416,182 Shares of StockSeptember 24 at 5:00 AM | insidertrades.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 416,182 SharesSeptember 23 at 10:17 PM | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 611,000 SharesSeptember 23 at 10:17 PM | marketbeat.comInsider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 683,818 Shares of StockSeptember 23 at 10:17 PM | marketbeat.comAre You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd.September 23 at 1:01 PM | zacks.comRoivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call TranscriptSeptember 23 at 6:00 AM | seekingalpha.comBrokers Issue Forecasts for ROIV Q1 EarningsSeptember 22 at 2:45 AM | marketbeat.comQ2 EPS Forecast for Roivant Sciences Increased by AnalystSeptember 22 at 2:31 AM | americanbankingnews.comLeerink Partnrs Issues Optimistic Forecast for ROIV EarningsSeptember 22 at 2:29 AM | marketbeat.comThe Goldman Sachs Group Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) StockSeptember 20, 2025 | americanbankingnews.comHC Wainwright Boosts Roivant Sciences (NASDAQ:ROIV) Price Target to $20.00September 20, 2025 | americanbankingnews.comLeerink Partners Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) StockSeptember 20, 2025 | americanbankingnews.comGuggenheim Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) StockSeptember 20, 2025 | americanbankingnews.comBank of America Raises Roivant Sciences (NASDAQ:ROIV) Price Target to $16.50September 20, 2025 | americanbankingnews.comMatthew Gline Purchases 3,315 Shares of Roivant Sciences (NASDAQ:ROIV) StockSeptember 19, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Price Target Raised to $24.00September 19, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Given New $20.00 Price Target at JPMorgan Chase & Co.September 19, 2025 | marketbeat.comGuggenheim Increases Roivant Sciences (NASDAQ:ROIV) Price Target to $21.00September 19, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Price Target Raised to $22.00 at Leerink PartnersSeptember 19, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Given New $16.50 Price Target at Bank of AmericaSeptember 19, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock PriceSeptember 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025NVIDIA Stock Could Pull Back in September, But Don’t Bet on ItBy Thomas Hughes | August 28, 2025ACM Research: Why This Chinese Chip Stock Is Just Getting StartedBy Jeffrey Neal Johnson | September 1, 2025OGN, QGEN, BBIO, and ROIV Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$51.26 -0.24 (-0.46%) As of 11:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Organon & Co. NYSE:OGN$10.36 -0.19 (-1.76%) As of 11:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.QIAGEN NYSE:QGEN$45.13 -0.48 (-1.05%) As of 11:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Roivant Sciences NASDAQ:ROIV$14.62 -0.12 (-0.78%) As of 11:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm’s RSI Just Hit Its High of the Year—Why That’s Bullish 2 Ways to Trade Amazon Ahead of October’s Prime Day AutoZone Pulls Into a Buy-the-Dip Opportunity Rocket Lab’s Bullish Case Remains Intact Despite Recent Offering Broadcom Price Targets Just Reached Above $400 for the First Time These 3 Mega-Cap Giants Just Increased Dividends by 7% or More 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
